by Ethan Huff, DC Clothesline:
The dreaded “new” disease known as RSV, short for respiratory syncytial virus, is the target of Pfizer’s new RSV vaccine, called “Abrysvo” – but are Americans aware of the true history of RSV and how it is actually caused by Big Pharma’s polio vaccines of old?
It is true. The polio vaccines our parents and grandparents received contained a monkey virus called the coryza virus that, once it was injected into tens of millions of bodies, the medical establishment quietly renamed it as RSV to hide its true origins as a vaccine-induced illness.
Most of America has no clue that RSV is basically a vaccine side effect, even as millions are herded into taking Abrysvo for their own “protection.”
TRUTH LIVES on at https://sgtreport.tv/
On Aug. 21, 2023, the U.S. Food and Drug Administration (FDA) quietly approved Abrysvo. Pregnant mothers are being told to take it despite the fact that it greatly increases the risk of pre-term birth and all of the short- and long-term health complications for the baby that often ensue.
Had polio vaccines never been widely administered, followed by a slew of other vaccines over the years that contain hidden viruses of their own, i.e., simian virus 40 (SV40), there probably would not even be an RSV “crisis,” assuming one is real, in the first place.
Even so, Pfizer was given the green light to peddle yet another death drug on the masses, which the company proudly announced is the only RSV injection currently on the market for elderly people and pregnant mothers.
“Pfizer currently is the only company with an RSV vaccine to help older adults, as well as infants through maternal immunization,” Pfizer boasted back in September.
(Related: Back in 2022, experts Lyn Redwood, RN, MSN, Dr. Meryl Nass and Dr. Ryan Cole issued a warning to presidential contender Robert F. Kennedy, Jr., that RSV vaccines must be stopped because they are dangerous.)
EU approves Abrysvo for adults 60 and older, pregnant mothers
Just two days after the FDA green-lighted Abrysvo here in the States, the European Union (EU) granted bloc-wide market authorization for the drug to similarly be administered there to adults 60 and over, as well as to pregnant mothers.
About a month after that, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) gave the green light to Abrysvo for basically these same demographics as well, this following a Joint Committee on Vaccination and Immunisation (JCVI) recommendation.
